Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2020-08-20 Regulatory Filings
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Response to ASX price query 4 pages 674.6KB
Regulatory Filings Classification · 100% confidence The document is a letter from the Australian Securities Exchange (ASX) to Neurotech International Limited (NTI) regarding a price query about unusual trading activity in NTI's shares. The letter requests information from NTI about any undisclosed material information that could explain the trading, compliance with listing rules, and the possibility of a trading halt. The response letter from NTI addresses these queries and confirms compliance with listing rules and disclosure policies. There is no financial data, earnings information, or report content; rather, this is a regulatory compliance correspondence related to market disclosure and trading activity. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2020-08-20 English
Trading Halt 2 pages 161.3KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Neurotech International Limited regarding a request for a trading halt on its securities pending the release of an announcement. It references compliance with ASX Listing Rule 3.1 and mentions pending results of laboratory testing. The document is short (2137 characters) and does not contain any financial data, financial statements, or detailed report content. It is clearly an announcement about a trading halt and an upcoming announcement, not the announcement or report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2020-08-18 English
Ceasing to be a substantial holder 1 page 413.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 under the Corporations Act 2001, titled 'Notice of ceasing to be a substantial holder.' It details changes in relevant interests and associations related to substantial shareholdings in a company. This type of filing is a notification about changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is not an annual report, audit report, or any other financial report but a regulatory notice about shareholding changes.
2020-08-03 English
Quarterly Report and Appendix 4C 9 pages 393.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Report for the period ended 30 June 2020' and contains detailed operational updates, project descriptions, corporate actions including placements and debt conversion, and an Appendix 4C cash flow report as required by ASX Listing Rule 4.7B. The content includes substantive financial data such as cash flow statements and detailed business activities for the quarter. This matches the characteristics of an Interim / Quarterly Report (IR) rather than a brief announcement or a full annual report. The length (15,000 characters) and detailed financial and operational information confirm it is a comprehensive quarterly report, not just an announcement or summary. Therefore, the correct classification is Interim / Quarterly Report (IR). Q4 2020
2020-07-29 English
Notice of General Meeting/Proxy Form 37 pages 1.2MB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Notice of Extraordinary General Meeting (EGM) including a Proxy Form and Explanatory Statement. It contains detailed information about the meeting date, location, agenda items, resolutions to be voted on, voting instructions, and proxy appointment details. The content is focused on informing shareholders about the meeting and soliciting their votes on specific corporate actions such as share issues and director fees. There are no financial statements, earnings data, or management discussion of financial results. The document is not a report of financial performance or audit, nor is it a transcript or presentation. It is a formal meeting notice and proxy solicitation document. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and detailed content confirm it is the actual proxy statement, not just an announcement of a meeting or report publication.
2020-07-27 English
Neurotech commences assays on Dolce cannabis strains 3 pages 194.3KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 27 July 2020 from Neurotech International Limited. It provides an update on the company's commencement of profiling assays on proprietary cannabis strains for medicinal use targeting autism and other neurological disorders. The content focuses on the initiation of research activities, shipment of strains for analysis, and plans for future testing and clinical trials. There are no financial statements, earnings data, or detailed financial analysis present. The document is an operational update about a new project and research progress rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is also not a regulatory filing or legal proceeding. The document is a general company announcement about a new research initiative and progress, which aligns best with the Regulatory Filings (RNS) category as a general announcement that does not fit other specific categories.
2020-07-26 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.